Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Biogen Pharma

Pharmaceutical manufacturer · Islamabad · Pakistan

Islamabad-based pharmaceutical manufacturer producing human and veterinary healthcare products.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date20 Aug 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
260 Industrial Triangle, Kahuta Road, Islamabad, Pakistan
Phone
+92 51 4493471; +92 51 4493481
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000639 Biogen Pharma. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000639 78 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx79public portfolio records represented
REG69unique registrations represented
IDX78indexed MedInfoBase presentations
SRC1additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR78current validated price records
G39generic molecules in indexed catalogue
DF8dosage-form groups
TA10therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage99%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage94%
priced packs safely normalized per unit
Comparable-market coverage90%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixBiogen PharmaShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/biogen-pharmaGenerated 23 Sep 2026Anti-infectives43 · 55%CNS & mental health15 · 19%Dermatology10 · 13%Vitamins, minerals & nutrition2 · 3%Reproductive & genitourinary2 · 3%Gastrointestinal & hepatology2 · 3%Anesthesia & critical care1 · 1%Other therapeutic areas3 · 4%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioBiogen PharmaDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/biogen-pharmaGenerated 23 Sep 202678presentationsTablet39 · 50%Injection19 · 24%Cream11 · 14%Ointment3 · 4%Capsule2 · 3%Suspension2 · 3%Other forms2 · 3%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionBiogen PharmaCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/biogen-pharmaGenerated 23 Sep 202670comparable productsBelow peer median20 · 29%Near peer median35 · 50%Above peer median15 · 21%Company median price position+0.2%Lowest-price equivalents6Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsBiogen PharmaCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/biogen-pharmaGenerated 23 Sep 2026Bio-Labs(Pvt) Ltd29 shared74% overlapValor Pharmaceuticals28 shared72% overlapPharmasol (Pvt) Ltd.27 shared69% overlapNabiqasim Industries (Pvt) Ltd.,26 shared67% overlapM/s. Genix Pharma (Pvt) Ltd.26 shared67% overlapNeutro Pharma (Pvt.) Ltd.,26 shared67% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives43 products · 55%
CNS & mental health15 products · 19%
Dermatology10 products · 13%
Vitamins, minerals & nutrition2 products · 3%
Reproductive & genitourinary2 products · 3%
Gastrointestinal & hepatology2 products · 3%
Anesthesia & critical care1 products · 1%
Oncology & immunology1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins12 products · 15%
Topical corticosteroids / anti-inflammatory dermatologics9 products · 12%
Antiepileptics9 products · 12%
Fluoroquinolone antibacterials8 products · 10%
Antipsychotics6 products · 8%
Other systemic antibacterials4 products · 5%
Antifungals4 products · 5%
Macrolide antibacterials3 products · 4%
Formulation footprint

Dosage forms

Tablet39 products
Injection19 products
Cream11 products
Ointment3 products
Capsule2 products
Suspension2 products
Infusion1 products
Lotion1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 LevecetamLevetiracetam 6presentations 250 mg, 500 mg, 750 mg · Tablet #2 BidonRisperidone 4presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #3 BiozonBetamethasone 4presentations 0.1 %, 0.1% · Ointment, Cream #4 BiotroxoneCeftriaxone 3presentations 1 g, 250 mg, 500 mg · Injection #5 Gem-CotHydrocortisone 3presentations 1 %, 1% · Cream #6 GendimeCeftazidime 3presentations 1 g, 250 mg, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2029% of comparable products
Near market median35within ±5% of median
Above market median1521% of comparable products
Lowest-price equivalents6ties included
Company median price position +0.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Gem-Cot 1 %Hydrocortisone · Cream · 20gm PKR 2.49/g-57.0% vs market median Gem-Cot 1 %Hydrocortisone · Cream · 10gm PKR 2.99/g-48.4% vs market median Gem-Cot 1%Hydrocortisone · Cream · 5gm PKR 3.99/g-40.8% vs market median Sulzin 1%Sulphadiazine · Cream · 50gm PKR 3.19/g-37.0% vs market median Carbamazapine Carbamazapine 400 mgCarbamazepine · Tablet · 50's PKR 11.86/tablet-34.1% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Bio-Labs(Pvt) Ltd236 products · 82 generics 29shared generics Valor Pharmaceuticals219 products · 97 generics 28shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 27shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 26shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 26shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 26shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers68Distinct registrations among indexed, published, presentation-validated products only
Verified price observations144
Products with a verified price78
Products with multiple price observations66
Source records with multiple versions78
Latest portfolio source check22 Sep 2026
Latest effective price date20 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

69 unique registration(s) · 78 indexed presentation(s) · 1 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Artecid Artemether + Lumefantrine 40 mg + 240 mg Tablet 8’s 068524 PKR 543.79 PKR 67.97/tablet 6% above median
Artecid Artemether + Lumefantrine 20 mg + 120 mg Tablet 16’s 070205 PKR 638.33 PKR 39.90/tablet Near median
Atorium Atracurium besylate 10 mg/mL Injection 5mlx1's Ampoule 124499 PKR 269.30 — No comparator
Bactogen Mupirocin 2% Cream 15gm 070178 PKR 219.43 PKR 14.63/g 15% below median
Bekum Meropenem 1 g IV injection 1's 119421 PKR 3,801.78 PKR 3,801.78/vial/unit Near median
Bekum Meropenem 500 mg IV injection 1's 119422 PKR 2,033.95 PKR 2,033.95/vial/unit Near median
Bidon Risperidone 1 mg Tablet 10’s 073144 PKR 239.37 PKR 23.94/tablet Near median
Bidon Risperidone 4 mg Tablet 10’s 073145 PKR 777.96 PKR 77.80/tablet 8% above median
Bidon Risperidone 2 mg Tablet 10’s 075323 PKR 388.98 PKR 38.90/tablet 6% above median
Bidon Risperidone 3 mg Tablet 10’s 075324 PKR 598.43 PKR 59.84/tablet Near median
Biopine Clozapine 25 mg Tablet 50’s 073148 PKR 1,595.82 PKR 31.92/tablet Near median
Biopine Clozapine 100 mg Tablet 50’s 073149 PKR 3,490.85 PKR 69.82/tablet Near median
Biothate Colistimethate sodium 1 MIU IV injection 1’s 117616 PKR 1,143.33 PKR 1,143.33/vial/unit Near median
Biothate Colistimethate sodium 100 mg Injection 1's 124501 PKR 3,000.77 PKR 3,000.77/vial/unit No comparator
BiothateSource observed Colistimethate sodium 1 MIU Injection 1's 131532Official source ↗ No indexed price — —
Biotraxone Ceftriaxone 2 g IV injection 1’s 117618 PKR 855.36 PKR 855.36/vial/unit Near median
Biotroxone Ceftriaxone 250 mg Injection Vial 056775 PKR 201.46 PKR 201.46/vial/unit Near median
Biotroxone Ceftriaxone 500 mg Injection Vial 056776 PKR 339.09 PKR 339.09/vial/unit Near median
Biotroxone Ceftriaxone 1 g Injection Vial 056777 PKR 640.32 PKR 640.32/vial/unit 7% above median
Biozon Betamethasone 0.1% Cream 5gm 066411 PKR 21.94 PKR 4.39/g Near median
Biozon Betamethasone 0.1% Cream 15gm 066411 PKR 59.84 PKR 3.99/g 13% below median
Biozon Betamethasone 0.1% Ointment 15gm 066412 PKR 59.84 PKR 3.99/g 19% below median
Biozon Betamethasone 0.1 % Ointment 5gm 066412 PKR 21.94 PKR 4.39/g 7% below median
Blitz Azithromycin 250 mg Tablet 6’s 063479 PKR 299.21 PKR 49.87/tablet 6% above median
Carbamazapine Carbamazapine Carbamazepine 400 mg Tablet 50's 119666 PKR 592.79 PKR 11.86/tablet 34% below median
Cleiro Clarithromycin 500 mg Tablet 10’s 068525 PKR 887.68 PKR 88.77/tablet 6% above median
Cleiro Clarithromycin 250 mg Tablet 10’s 070204 PKR 478.75 PKR 47.88/tablet Near median
Cortisin Hydrocortisone 100 mg Injection 1's 121426 PKR 90.81 PKR 90.81/vial/unit 28% below median
Cortisin Hydrocortisone 250 mg Injection 1's 121427 PKR 158.73 PKR 158.73/vial/unit 11% below median
Dapsin Dapsone 25 mg Tablet 10’s 068827 PKR 19.95 PKR 2.00/tablet No comparator
Dapsin Dapsone 100 mg Tablet 10’s 068828 PKR 55.85 PKR 5.59/tablet No comparator
Entegen Entecavir 0.5 mg Tablet 30’s 070184 PKR 20,346.71 PKR 678.22/tablet 90% above median
Fresno Clotrimazole 500 mg Tablet 1's 063480 PKR 121.66 PKR 121.66/tablet Near median
Fresno Clotrimazole 2% Cream 35gm 072034 PKR 119.69 PKR 3.42/g 22% below median
Gem-Cot Hydrocortisone 1 % Cream 20gm 070196 PKR 49.87 PKR 2.49/g 57% below median
Gem-Cot Hydrocortisone 1% Cream 5gm 070196 PKR 19.95 PKR 3.99/g 41% below median
Gem-Cot Hydrocortisone 1 % Cream 10gm 070196 PKR 29.92 PKR 2.99/g 48% below median
Gendime Ceftazidime 250 mg Injection Vial 056778 PKR 167.84 PKR 167.84/vial/unit Near median
Gendime Ceftazidime 500 mg Injection Vial 056779 PKR 255.31 PKR 255.31/vial/unit Near median
Gendime Ceftazidime 1 g Injection Vial 056780 PKR 479.57 PKR 479.57/vial/unit Near median
Genexime Cefotaxime 250 mg IM/IV injection Vial 056770 PKR 110.89 PKR 110.89/vial/unit Near median
Genexime Cefotaxime 500 mg Injection Vial 056771 PKR 175.40 PKR 175.40/vial/unit 10% above median
Genictal Lamotrigine = 50 mg Tablet 30's 116641 PKR 797.91 PKR 26.60/tablet Near median
Genictal Lamotrigine = 100 mg Tablet 30's 116642 PKR 997.38 PKR 33.25/tablet Near median
Hygrade Levofloxacin 250 mg Tablet 10's 063474 PKR 475.22 PKR 47.52/tablet Near median
Hygrade Levofloxacin 500 mg Tablet 10's 063475 PKR 790.76 PKR 79.08/tablet Near median
Hygrade Levofloxacin 750 mg Tablet 10’s 063476 PKR 997.39 PKR 99.74/tablet 7% above median
Letramed Letrozole 2.5 mg Tablet 30’s 087598 PKR 11,968.18 PKR 398.94/tablet Near median
Levecetam Levetiracetam 250 mg Tablet 30's 070216 PKR 1,569.83 PKR 52.33/tablet 5% below median
Levecetam Levetiracetam 250 mg Tablet 10's, 070216 PKR 522.61 — No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Biogen Pharma — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/biogen-pharma/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.